Bupropion for the Treatment of Methamphetamine Dependence - 1 - Full Text View

Bupropion for the Treatment of Methamphetamine Dependence - 1

This study has been completed.

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00069251

Purpose

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

Condition	Intervention	Phase
Amphetamine-Related Disorders	Drug: Bupropion	Phase II

MedlinePlus related topics:

Methamphetamine

Drug Information available for:

Bupropion hydrochloride Bupropion Methamphetamine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Bupropion for the Treatment of Methamphetamine Dependence

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Severity addiction
Methamphetamine use

Estimated Enrollment:	150
Study Start Date:	July 2003
Estimated Study Completion Date:	June 2005

Detailed Description:

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
Subject must be willing to comply with study procedures.
Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
Be able to comply with protocol requirements

Exclusion Criteria:

Please contact site for more information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00069251

Locations


United States, California
	South Bay Treatment Center
	San Diego, California, United States, 92105
	Matrix Institute on Addictions
	Costa Mesa, California, United States, 92627

United States, Hawaii
	Pacific Addiction Research Center
	Honolulu, Hawaii, United States, 96813

United States, Iowa
	Powell Chemical Dependency Center
	Des Moines, Iowa, United States, 50316

United States, Missouri
	University of Missouri - Kansas City
	Kansas City, Missouri, United States, 64108

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators


Principal Investigator:	Richard Rawson, Ph.D.	University of California, Los Angeles

More Information

Study ID Numbers:	NIDA-CTO-0008-1
First Received:	September 18, 2003
Last Updated:	July 21, 2008
ClinicalTrials.gov Identifier:	NCT00069251
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Methamphetamine

Dopamine

Mental Disorders

Amphetamine-Related Disorders

Bupropion

Substance-Related Disorders

Disorders of Environmental Origin

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors

Neurotransmitter Uptake Inhibitors

Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action

Adrenergic Agents

Sympathomimetics

Adrenergic Uptake Inhibitors

Physiological Effects of Drugs

Psychotropic Drugs

Central Nervous System Stimulants

Pharmacologic Actions

Autonomic Agents

Therapeutic Uses

Dopamine Agents

Peripheral Nervous System Agents

Antidepressive Agents, Second-Generation

Central Nervous System Agents

Antidepressive Agents

ClinicalTrials.gov processed this record on November 30, 2008